Alkali Or Alkaline Earth Chloride (e.g., Barium Or Lithium Chloride, Etc.) Patents (Class 424/677)
  • Patent number: 10271566
    Abstract: A method for minimizing or preventing the induction of stress-related or stress-induced inappetance or inanition in an animal selected for a marketing or management practice.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: April 30, 2019
    Assignee: CHARLES STURT UNIVERSITY
    Inventors: Jane Quinn, Scott Edwards, Martin Combs
  • Patent number: 10047386
    Abstract: Methods for detecting abdominal aortic aneurysm (AAA) or predisposition to AAA in a apoE subject, methods for monitoring the efficacy of treatment of AAA in a subject, and methods for evaluating the severity of AAA or risk of AAA in a subject involve measuring the amount of tetrahydrobiopterin (H4B) present in the test sample and comparing it to the amount of H4B present in a standard or previous test sample. A decreased amount of H4B present in the test sample compared to the standard is indicative of AAA or predisposition to AAA. Treatment can be administered to the subject prior to a second time point, and an increased amount of H4B present in the second test sample compared to the first test sample is indicative of effective treatment of AAA. Candidates can be identified for further testing or monitoring for AAA, and/or for treatment for AAA.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: August 14, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Hua Cai
  • Patent number: 9572851
    Abstract: The present invention relates to a pharmaceutical composition for treating drug addiction comprising herb Gelsemium elegans Benth. and the flower of herb Datura metel L., and optionally any pharmaceutically acceptable excipient, wherein the weight/weight ratio of the raw material of Gelsemium elegans Benth. to the raw material of the flower of Datura metel is from 2:1 to 6:1.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: February 21, 2017
    Assignee: YUNNAN MINGJINGHENGLI PHARMACEUTICAL CO., LTD.
    Inventor: Kaiyi Chang
  • Patent number: 9498547
    Abstract: The invention relates to a water-based biocompatible non-cytotoxic preparation for the selective staining of internal limiting membrane (ILM) and/or epiretinal membranes (ERM) in the human or animal eye, and to a kit containing said water-based preparation according to the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: November 22, 2016
    Assignee: Fluoron GMBH
    Inventors: Christian Lingenfelder, Bastian Theisinger, Wilfried Hiebl, Nadine Hagedorn
  • Publication number: 20150132351
    Abstract: Methods of using a polymeric composition are described for preventing or reducing the signs of aging. The polymeric composition can include a polymer matrix and one or a plurality of mineral filler(s), uniformly dispersed in the polymer matrix, having properties of absorption and/or emission in the far infrared region ranging from 2 ?m to 20 ?m.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 14, 2015
    Inventors: Thomas Gonzaga Canova, Gabriel Gorescu, Tarcis Cordeiro Bastos
  • Publication number: 20150099012
    Abstract: The present invention relates to a method for increasing retrovirus transcription in an infected eukaryotic cell, comprising increasing Wnt pathway signaling in said cell such that transcription of said retrovirus is increased. Also, the present invention relates to a method of treating a subject infected with a retrovirus, said method comprising administering to said subject an activator of the Wnt pathway in an amount that increased Wnt pathway signaling in resting memory CD4+ T cells of said subject such that the retroviral long terminal repeat (LTR) in said cells is activated or de-repressed.
    Type: Application
    Filed: March 1, 2013
    Publication date: April 9, 2015
    Inventor: Tokameh Mahmoudi
  • Patent number: 8999297
    Abstract: A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: April 7, 2015
    Assignee: Inter-Med, Inc.
    Inventors: Gary J. Pond, John Baeten
  • Publication number: 20150044302
    Abstract: The present invention relates to a method of suppressing appetite or promoting a stimulant effect in an individual in need thereof, comprising administering to the individual per 24 hour period an effective amount of one or more alkali metals selected from the group consisting of one or more sources of cesium, one or more sources of rubidium, one or more sources of lithium, and combinations thereof. The present invention further relates to weight loss or stimulant compositions comprising one or more alkali metals.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 12, 2015
    Applicant: ASHBERRY INTERNATIONAL LIMITED
    Inventor: Arnold Forbes
  • Publication number: 20150004255
    Abstract: The present invention relates to a peritoneal dialysis fluid comprising a compound inhibiting glycogen synthase kinase (GSK)-3 activity, in particular (GSK)-3? activity, for use in the prevention of infectious and non-infectious peritoneal complications such as peritonitis, peritoneal membrane injury, damage and failure, barrier dysfunction and mesothelial cell detachment.
    Type: Application
    Filed: December 19, 2012
    Publication date: January 1, 2015
    Inventors: Krisztina Szilvia Rusai, Christoph Aufricht
  • Patent number: 8911724
    Abstract: Provided are methods and compositions for increasing CD4+ cell count in mammals, preferably by at least 25%, while undergoing treatment for various conditions whose treatment can have detrimental effects on immune system function. Such conditions include, but are not limited to, HIV infection, cancer, and hepatitis. The compositions include alpha lipoic acid; acetyl L-carnitine; N-acetyl-cysteine; and optionally: zinc, selenium, vitamin C, bioflavinoid complex, vitamin E, co-enzyme Q10, glutathione, beta-carotene, vitamin A, vitamin B1, vitamin B2, vitamin B6, niacinamide, calcium pantothenate, folic acid, vitamin B12, copper, manganese, chromium, and molybdenum.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 16, 2014
    Assignee: K-PAX Pharmaceuticals, Inc.
    Inventor: Jon D. Kaiser
  • Patent number: 8883762
    Abstract: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. Glucose-like degradation and hydrolysis is avoided during sterilization and storage, while maintenance of a neutral mixture pH is achieved by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further discloses a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: November 11, 2014
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventor: Thomas Zimmeck
  • Publication number: 20140322358
    Abstract: The present invention is generally directed to compositions and methods for amelioration chronic renal failure and related symptoms in domestic animals. In one case, the present invention is directed to a composition for the treatment of chronic renal failure in a domestic animal or symptoms related to chronic renal failure. The composition comprises a Fruit- and Vegetable-Based Additive. In another case, the present invention is directed to a composition for the treatment of chronic renal failure in a domestic animal or symptoms related to chronic renal failure. The composition comprises a Cesium and/or Rubidium salt. In another case, the present invention is directed to a composition for the treatment of chronic renal failure in a domestic animal or symptoms related to chronic renal failure. The composition comprises a Dehydrated Domestic Animal Food and a Phosphate Binder.
    Type: Application
    Filed: April 24, 2014
    Publication date: October 30, 2014
    Inventor: Jeffrey Alan McKinney
  • Patent number: 8835508
    Abstract: A stable aqueous solution of sodium pyruvate for medical use, which contains 10-1,200 mM sodium pyruvate and a stabilizer of sodium pyruvate, wherein the said stabilizer is H+ which leads to pH 3.0-6.0 or NaCl which provides at least 20 mM Na+.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: September 16, 2014
    Inventor: Fangqiang Zhou
  • Publication number: 20140242193
    Abstract: 2:1 cocrystals of amino acids and Li+ salts crystallize from hot water to afford water stable cationic networks based upon tetrahedral lithium cations: bilayered square grids, a lithium zeolitic metal-organic material (LiZMOM) and several lithium diamondoid metal-organic materials (LiDMOMs). The compositions may be used as a pharmaceutical for the treatment of suicidality and other disorders that require lithium to penetrate the blood brain barrier and exert therapeutic effects in the CNS. Advantageously, the novel cocrystal forms described herein may be used to lower the oral dose required to achieve therapeutic concentrations of lithium in the brain, thus reducing the peripheral toxicity and potentially broadening the therapeutic index in comparison to conventional lithium forms.
    Type: Application
    Filed: March 26, 2012
    Publication date: August 28, 2014
    Applicant: University of South Florida
    Inventors: Michael John Zaworotko, Roland D. Shytle, Tien Teng Ong, Padmini Kavuru, Ryan N. Cantwell, Tranhha Nguyen, Adam John Smith
  • Patent number: 8815304
    Abstract: The present invention relates to a method of suppressing appetite or promoting a stimulant effect in an individual in need thereof, comprising administering to the individual per 24 hour period an effective amount of one or more alkali metals selected from the group consisting of one or more sources of cesium, one or more sources of rubidium, one or more sources of lithium, and combinations thereof. The present invention further relates to weight loss or stimulant compositions comprising one or more alkali metals.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: August 26, 2014
    Assignee: Ashberry International Limited
    Inventor: Arnold Forbes
  • Publication number: 20140193523
    Abstract: Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage.
    Type: Application
    Filed: January 6, 2014
    Publication date: July 10, 2014
    Inventor: James Lorne HENRY
  • Patent number: 8771754
    Abstract: The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity to vascular endothelial cells, and/or neuron death associated with radiation therapy alone.
    Type: Grant
    Filed: September 19, 2005
    Date of Patent: July 8, 2014
    Assignee: Vanderbilt University
    Inventor: Dennis E. Hallahan
  • Publication number: 20140120182
    Abstract: The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumours can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesised that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death.
    Type: Application
    Filed: March 5, 2013
    Publication date: May 1, 2014
    Applicant: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK
    Inventor: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK
  • Patent number: 8709500
    Abstract: A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl2(OH)6]+. The drug delivery system has use in the delivery of drugs such as 4-biphenylacetic acid, Diclofenac, Gemfibrozil, Ibuprofen, Naproxen, 2-Propylpentanoic acid and Tolfenamic acid.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: April 29, 2014
    Assignee: Isis Innovation Limited
    Inventor: Dermot Michael O'Hare
  • Patent number: 8703211
    Abstract: The invention relates to the treatment and prophylaxis of cancer. In particular, the invention relates to a pharmaceutical agent comprising strontium, amino acid(s) and mineral element(s), and its use in the preparation of an agent useful for the treatment and prophylaxis of cancer. The invention also relates to a method for treatment and prophylaxis of cancer.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: April 22, 2014
    Assignee: Oy Neurofood AB
    Inventor: Thomas Tallberg
  • Publication number: 20140056998
    Abstract: An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder. The genetic assay, with or without a biopterin or BH4 system assay, may also be used to determine treatment regimens. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.
    Type: Application
    Filed: November 1, 2013
    Publication date: February 27, 2014
    Applicant: The Research Foundation for Mental Hygiene
    Inventors: James D. Clelland, Catherine L. Clelland
  • Publication number: 20140037757
    Abstract: The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided.
    Type: Application
    Filed: April 27, 2012
    Publication date: February 6, 2014
    Inventors: Barbara Ehrlich, Sara Rockwell, Jennifer Benbow
  • Patent number: 8637083
    Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: January 28, 2014
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
  • Publication number: 20130337052
    Abstract: Administering a therapeutically effective dose of lithium ions mitigates the side effects of a psychoactive substance such as a cannabinoid. The therapeutically effective dose of lithium ions includes greater than 4 milligrams of lithium and less than 170 milligrams of lithium, or includes between 8 and 32 milligrams of lithium ions per milligram of the psychoactive substance. The therapeutically effective dose of lithium ions is administered using lithium carbonate, lithium citrate, lithium chloride, lithium orotate, lithium aspartate, or analogs thereof using a delivery vehicle selected from pills, tablets, capsules, gelcaps, liquids, syrups, injectable liquids, powders, or foods and administered prior to, with, or after administration of the psychoactive substance. The psychoactive substance includes one or more of anandamide, 2-arachidonoyl glycerol, 2-arachidonoyl glycerol ether, tetrahydrocannabinol, cannabinol, cannabidiol, or analogs thereof and may be administered using the delivery vehicle.
    Type: Application
    Filed: September 24, 2012
    Publication date: December 19, 2013
    Inventors: Patricia Linert, Kenneth J. Ouimet
  • Patent number: 8603535
    Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: December 10, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
  • Patent number: 8603542
    Abstract: Methods and compositions for treating skin conditions in animals, which tend to have higher skin pH than humans, including wounds, ulcers, rashes, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates the use of an aqueous or emollient medium having non-occlusive properties with one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: December 10, 2013
    Assignee: Penguin IP Holdings Inc.
    Inventor: Jennifer Bartels
  • Publication number: 20130309380
    Abstract: Methods of preserving fresh produce with a produce preservative which extends the shelf life of fresh produce, particularly cut fresh produce, and preserves the texture, flavor, appearance, crispness, and color of the fresh produce, particularly the exposed surface of the fresh produce, are provided. The method comprises: providing a solution of produce preservative comprising: water; a preservative cation which is selected from the group consisting of a strontium ion, lithium ion, barium ion, aluminum ion, copper ion, ammonium ion, iron ion, manganese ion, potassium ion, or mixtures thereof; and ascorbate ions, or erythorbate ions; wherein the ascorbate ions or erythorbate ions and the preservative cation are present in an ion ratio of preferably from 0.2:1 to 8:1, more preferably 0.75:1 to 8:1, even more preferably from 1:1 to 4:1, yet more preferably 1.5:1 to 3:1; most preferably 1.1:1 to 2.5:1; and, applying said produce preservative to the produce.
    Type: Application
    Filed: July 26, 2013
    Publication date: November 21, 2013
    Applicant: NatureSeal, Inc.
    Inventors: Chao Chen, Xiaoling Dong, Kenneth James
  • Publication number: 20130295201
    Abstract: Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed.
    Type: Application
    Filed: May 28, 2013
    Publication date: November 7, 2013
    Applicant: Cosmederm Bioscience, Inc.
    Inventors: Gary S. HAHN, David O. Thueson
  • Patent number: 8546423
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: October 1, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Patent number: 8524735
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: September 3, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Patent number: 8524734
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: September 3, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Publication number: 20130149390
    Abstract: The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.
    Type: Application
    Filed: December 7, 2012
    Publication date: June 13, 2013
    Applicant: MSM INNOVATIONS, INC.
    Inventor: MSM INNOVATIONS, INC.
  • Patent number: 8431587
    Abstract: The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumours can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesised that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: April 30, 2013
    Assignee: University College Cork, National University of Ireland, Cork
    Inventors: Sharon McKenna, Gerald C. O'Sullivan, Tracey O'Donovan
  • Patent number: 8409628
    Abstract: Methods and compositions for treating wounds, decubitus ulcers, diaper rash, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates in one embodiment the use of an aqueous or emollient medium having one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: April 2, 2013
    Assignee: Penguin IP Holdings, Inc.
    Inventor: Jennifer Bartels
  • Patent number: 8404262
    Abstract: The present invention relates to improved compositions for controlling marine pest anemones, to methods of application of same, and to kits for the convenient dispensing of such compositions.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: March 26, 2013
    Assignee: Red Sea Fish Pharm Ltd.
    Inventor: Sharon Ram
  • Publication number: 20130039998
    Abstract: The present invention is directed to a composition comprising a modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.
    Type: Application
    Filed: December 23, 2009
    Publication date: February 14, 2013
    Applicants: UNIVERSITY OF WASHINGTON, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Daniel Fass, Stephen Haggarty, Edward Scolnick, Randall T. Moon, Travis L. Biechele, Nathan D. Camp
  • Patent number: 8357401
    Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: January 22, 2013
    Assignee: BIND Biosciences, Inc.
    Inventors: Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
  • Patent number: 8357696
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: January 22, 2013
    Assignee: Mpex Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
  • Publication number: 20130017274
    Abstract: In various embodiments methods of delaying the onset of and/or mitigating the severity of one or more symptoms of Parkinson's disease in a mammal are provided. In certain embodiments the methods involve administering to a mammal diagnosed as having or as at risk for Parkinson's disease a chronic low dose of lithium (e.g., a subtherapeutic dose). In certain embodiments the low dose lithium is administered in conjunction with another agent (e.g., L-DOPA).
    Type: Application
    Filed: March 16, 2012
    Publication date: January 17, 2013
    Applicant: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: JULIE K. ANDERSEN, HWAN KIM
  • Publication number: 20130004589
    Abstract: Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation/anion pair.
    Type: Application
    Filed: June 28, 2011
    Publication date: January 3, 2013
    Inventors: Connie B. Lin, Euen Thomas Graham Ekman Gunn, Ya-Ping Hu, Neema Kulkarni, Mary Catherine Mack
  • Patent number: 8273378
    Abstract: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: September 25, 2012
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Bruce L. Riser, Paul Zieske, Sujatha Karoor, Himanshu D. Patel
  • Publication number: 20120237475
    Abstract: Novel heterocyclic derivatives of formula (I): or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein Ra, n, R1 and R2 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5).
    Type: Application
    Filed: March 16, 2012
    Publication date: September 20, 2012
    Applicant: PROBIODRUG AG
    Inventors: Ulrich Heiser, Daniel Ramsbeck
  • Publication number: 20120237568
    Abstract: Methods of preparing bioactive composites are described. Also described are methods of molding such composites. Shaped bodies comprising bioactive composites are further described.
    Type: Application
    Filed: March 21, 2012
    Publication date: September 20, 2012
    Inventors: James P. Murphy, Erik M. Erbe, Charanpreet S. Bagga, Marissa M. Darmoc
  • Publication number: 20120231091
    Abstract: Provided is an efficient method of inducing differentiation of a pulp cell into an odontoblast. Also provided is an agent for inducing differentiation capable of inducing differentiation into an odontoblast efficiently. The method of inducing differentiation of a pulp cell into an odontoblast includes using a substance capable of activating a Wnt signaling pathway. Further, the agent for inducing differentiation includes a substance capable of activating a Wnt signaling pathway. Specifically, the substance capable of activating a Wnt signaling pathway is any one selected from sodium perchlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2.
    Type: Application
    Filed: November 16, 2010
    Publication date: September 13, 2012
    Applicant: National University Corporation Okayama University
    Inventors: Takashi Yamashiro, Hiroshi Kurosaka, Noriaki Kawanabe
  • Publication number: 20120219641
    Abstract: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.
    Type: Application
    Filed: February 14, 2012
    Publication date: August 30, 2012
    Applicant: ALBANY MOLECULAR RESEARCH, INC.
    Inventors: David D. Manning, Christopher Lawrence Cioffi
  • Publication number: 20120195860
    Abstract: The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof.
    Type: Application
    Filed: April 10, 2008
    Publication date: August 2, 2012
    Inventors: Tara Louise Walker, Perry Francis Bartlett
  • Publication number: 20120177750
    Abstract: Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 12, 2012
    Inventors: Gary S. HAHN, David O. Thueson
  • Publication number: 20120121680
    Abstract: Deicing products designed to deter ungulates are provided, along with methods of using those products to treat iced surfaces. The deicing product comprises a mixture of a deicer along with an ungulate repellent. The repellent can repel based on conditioned avoidance, fear, chemical irritation, and/or bad taste. The deicer can be a salt or a deicer solution. The invention is useful for deterring any ungulate that might be attracted to a component of the deicing product (e.g., the salt), but it is particularly useful for deterring deer.
    Type: Application
    Filed: October 18, 2011
    Publication date: May 17, 2012
    Applicant: NORTH AMERICAN SALT COMPANY
    Inventors: Neil Alexander Rosenburgh, Michelle Lee Daum, Jason Louis Bagley, Dan Pannell, Kristopher Shelite
  • Publication number: 20120114767
    Abstract: An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder. The genetic assay, with or without a biopterin or BH4 system assay, may also be used to determine treatment regimens. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.
    Type: Application
    Filed: December 12, 2011
    Publication date: May 10, 2012
    Applicant: THE RESEARCH FOUNDATION FOR MENTAL HYGIENE
    Inventors: James D. Clelland, Catherine L. Clelland
  • Publication number: 20110293746
    Abstract: There is provided methods and uses for promoting cell death, when combined with chemotherapeutic agents, in an abnormally proliferating cell, and for treating a proliferative disorder in a subject, which methods and uses involve contacting a cell with, or administering to a subject, an agent that modulates glycogen synthase kinase-3? activity to a cell that is being treated with a chemotherapeutic agent.
    Type: Application
    Filed: July 8, 2005
    Publication date: December 1, 2011
    Inventor: Qiang Yu